Twist Bioscience CEO sells shares for tax withholding
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a small mandated share sale tied to tax withholding.
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a small mandated share sale tied to tax withholding. On 2026-03-20, she sold 1,742 shares of common stock at an average price of $43.7864 per share to cover taxes due on vesting restricted stock units, as required under the company’s equity incentive plans and not as a discretionary trade. Following this transaction, she continued to hold 858,887 shares of common stock directly and also held employee stock options, including an award exercisable for 64,950 shares at an exercise price of $67.8500 expiring on 2030-08-31.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,742 shares
Net Sell
6 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
1,742 shs ($76K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,742 | $43.7864 | $76K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 858,887 shares (Direct);
Employee Stock Option (right to buy) — 64,950 contracts (Direct)
Footnotes (6)
- F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F6. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
FAQ
What insider transaction did Twist Bioscience (TWST) report for its CEO?
Twist Bioscience CEO Emily Leproust reported selling 1,742 common shares. The shares were sold on March 20, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units under the company’s equity incentive plans.
What stock options does the Twist Bioscience CEO still hold after this filing?
The CEO continues to hold employee stock options, including an award exercisable for 64,950 Twist Bioscience shares at a $67.8500 exercise price. These options expire on August 31, 2030, providing additional long-term equity exposure beyond her direct share ownership.
Does this Twist Bioscience Form 4 indicate a large reduction in the CEO’s stake?
No, the sale of 1,742 shares for tax withholding is small relative to the CEO’s 858,887 remaining shares. The transaction is characterized as a routine, mandated sell-to-cover event rather than a significant reduction of her overall ownership position in Twist Bioscience.
AI-generated analysis. How Rhea-AI works. Not financial advice.
